A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed
Advanced Malignancies (JIVAN).